Clinically, MTAP is highly frequently deleted, and MTA is significantly elevated in lung adenocarcinoma tissues compared to matched nonmalignant tissues (Wikoff et al, 2015; Fahrmann et al, 2017), highlighting the potential of MTAP/MTA as diagnostic markers and the unmet needs to explore the metabolomics and PTMomics of MTAP‐loss cancers for targeted therapy development. The gene discussed is MTAP; the disease is lung adenocarcinoma.